Future options for ALK-positive non-small cell lung cancer-Reference-Cited by-同舟云学术

Future options for ALK-positive non-small cell lung cancer

Published:2015-03 Issue:3 Volume:87 Page:211-219
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Iacono Daniela,Chiari Rita,Metro Giulio,Bennati Chiara,Bellezza Guido,Cenci Matteo,Ricciuti Biagio,Sidoni Angelo,Baglivo Sara,Minotti Vincenzo,Crinò Lucio

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference74 articles.

1. Novel molecular trends in the management of advanced non-small-cell lung cancer;Metro;Expert Rev Anticancer Ther,2012

2. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis;Shaw;Lancet Oncol,2011

3. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

4. ALK testing in non-small cell lung carcinoma: what now?;Kerr;J Thorac Oncol,2014

5. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer;Koivunen;Clin Cancer Res,2008

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors;Cancers;2022-12-11

2. Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis;Frontiers in Oncology;2022-11-03

3. Efficacy and treatment-related adverse events of multi-targeted tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials;International Journal of Clinical Pharmacy;2022-08-11

4. Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review and meta-analysis;Therapeutic Advances in Medical Oncology;2022-01

5. Bioactive PI3-kinase/Akt/mTOR Inhibitors in Targeted Lung Cancer Therapy;Advanced Pharmaceutical Bulletin;2021-10-09